Terumo India Launches TREO Abdominal Stent-Graft System

Terumo India Launches TREO Abdominal Stent-Graft System

Overview

Terumo India, the Indian subsidiary of Terumo Corporation, a global leader in medical technology, announced the launch of the TREO Stent-Graft System, an advanced solution for endovascular aneurysm repair (EVAR). Designed specifically for the treatment of infrarenal abdominal aortic aneurysms in adults with suitable anatomies, the TREO Stent-Graft System stands out as the only EVAR graft featuring both suprarenal and infrarenal active fixation.

 From the MD: Terumo India Private Limited

  • Shishir Agarwal, president and managing director of Terumo India Private Limited, commenting on the launch said: “In India, the prevalence of abdominal aortic aneurysms is rising, with an estimated 1 in 10,000 people affected annually, underscoring the significant need for advanced treatment options. At Terumo Aortic, we are 100% focused on addressing every patient's aortic needs and working together with doctors to find solutions that best fit individual anatomy.” “
  • Our continued focus on innovation is crucial in a market where the demand for reliable and effective endovascular solutions is growing, and we look forward to reinforcing our purpose of advancing healthcare and enhancing patient’s quality of life.”

About TREO

  • TREO is a three-piece design featuring in situ limb adjustability and provides a wide range of aortic device configurations to specifically address the anatomy of each individual patient. 
  • It features enhanced proximal sealing for improved stability and leak prevention, superior lock stent technology that offers robust fixation to reduce migration risks, and a flexible design that adapts to challenging and angulated anatomy. 
  • This enhances treatment flexibility, ensuring long-term performance and patient safety. Recent clinical studies show lower sac shrinkage and re-intervention rates.

From Terumo Aortic India (cardiovascular director)

  • Dharampal Singh Rawat, senior director - cardiovascular, Terumo Aortic India added, “The TREO Stent-Graft System exemplifies our commitment to advancing aortic care with its sophisticated design and unparalleled precision. The device's ability to be adjusted until securely in place, combined with its impressively high technical success rate, significantly reduces the risk of misplacement and ensures an optimal fit below the renal arteries.
  • This represents a significant advancement in our ability to address complex cases with greater accuracy and reliability. At Terumo Aortic, we are 100% focused on addressing every segment of the aorta, from the aortic root to the iliacs.

By bringing this innovative EVR, Terumo India continues to set new standards in providing solutions to challenging endovascular aneurysm repair.

 About Terumo India

  • Terumo India is a fast-growing medical devices company that serves to advance access to high-quality cardiac & vascular, and other medical devices for patients and medical practitioners in India. 
  • Terumo India is part of Terumo Corporation, a global leader in medical technology with headquarters in Tokyo, Japan. 
  • Established in 1921 and with its 100 years of history, Terumo’s starting point and unchanging corporate mission has been ‘Contributing to Society through Healthcare’.
  • Terumo India was established in 2013 with headquarters in Gurgaon, NCR Delhi and has since grown to touch over 100,000 lives with an expanding field force & distribution network.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!